Duchenne Muscular Dystrophy Approval Race: BioMarin Pulls Back Into Lead
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA advisory committee reviews for BioMarin’s drisapersen and Sarepta’s eteplirsen, once eyed as back-to-back meetings, are now set months apart. Draft guidance may help firms overcome previous findings of inadequate data.